Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pro-Pharmaceuticals has entered into a research collaboration with the University of Massachusetts Lowell to evaluate its leading compound, Davanat with chemotherapy drugs. The financial details have not been disclosed.
Subscribe to our email newsletter
Davanat is a new chemical entity of the galactomannan carbohydrate polymer family composed of mannose and galactose. Davanat, in combination with chemotherapies, is currently in Phase II trials for colorectal and biliary cancer.
David Platt, chairman and CEO, Pro-Pharmaceuticals, said: “Collaborating with the UML represents an exciting opportunity to partner with a premier academic institution. We continue to advance the development of Davanat, our lead product candidate in clinical trials, and the work from this collaboration will help further expand its potential as a first-in-class, targeted drug delivery system. Our goal is to improve the clinical benefit for patients by reducing the toxicity and improving the efficacy of chemotherapy regimens used to treat cancer.”